Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults

25 Mar 2024

Abstract excerpt

ABSTRACT mRNA-1647 is an investigational mRNA-based vaccine against cytomegalovirus (CMV) that contains sequences encoding the CMV proteins glycoprotein B and pentamer. Humoral and cellular immune responses were evaluated in blood samples collected from healthy CMV-seropositive and CMV-seronegative adults who participated in a phase 1 trial of a three-dose series of mRNA-1647 (NCT03382405). Neutralizing antibody...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Herpesvirus Infections and Treatments
Share to Parvovirus B19 Infection Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38526054
DOI: 10.1128/jvi.01603-23

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adultsPMID 38526054Read ↗

Safety and Immunogenicity of a Messenger RNA–Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical TrialSemantic proximity Read ↗

Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 VaccineSemantic proximity Read ↗

Shared Clinical and Immunologic Features of mRNA Vaccines: Preliminary Results from a Comparative Clinical StudySemantic proximity Read ↗

mRNA-based influenza vaccine expands breadth of B cell response in humansSemantic proximity Read ↗

Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19Semantic proximity Read ↗

Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseasesSemantic proximity Read ↗

Current Developments and Challenges of mRNA VaccinesSemantic proximity Read ↗

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccinesSemantic proximity Read ↗

Neutralizing antibody and T-cell spike targeted responses following receipt of a monovalent Omicron JN.1-adapted mRNA COVID-19 vaccine in immunosuppressed and healthy individualsSemantic proximity Read ↗

Systems biological assessment of human immunity to BNT162b2 mRNA vaccinationSemantic proximity Read ↗

Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infectionSemantic proximity Read ↗

Recombinant cytomegalovirus glycoprotein B vaccine: Rethinking the immunological basis of protectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.